tirzepatide landmark trial for masld Tirzepatide: First Approval | Drugs Read now: The SURPASS-EARLY trial
Description
I can order ongoing with confidence that Im getting what I paid for
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Your care team can adjust your plan at any time if needed
The primary endpoint is defined as the percentage of maintenance of body weight reduction, ranging from 0% to 100%, and the formula is provided in Table 1
Kaufman focused on the immune system
